96836 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
COMPOSITIONS AND METHODS FOR TREATING CANCER
#2IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF
#3IMMUNOGENIC COMPOSITIONS AND METHODS FOR REDUCING TRANSMISSION OF PATHOGENS
#4VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS
#5VETERINARY VACCINES AND METHODS FOR THE TREATMENT OF PASTEURELLA MULTOCIDA INFECTIONS IN FOOD PRODUCTION ANIMALS
#6PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING PASTEURELLA PROTEINS AND METHODS OF USE
#7IMPROVED CHIMERIC POLYPEPTIDES AND USES THEREOF
#8Methods and compositions for assessing antibody specificities
#9CONJUGATED VACCINE CARRIER PROTEINS
#10SEPTAPEPTIDES ASSOCIATED WITH NEURODEGENERACY
#11IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF
#12Methods and compositions for assessing antibody specificities
#13Proteins and immunizing compositions containing proteins and methods of use
#14HAEMOPHILUS INFLUENZAE VACCINE AND METHODS OF USE
#15METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES
#16ACTINOBACILLUS PLEUROPNEUMONIAE VACCINES
#17Reduced genome lacking toxin-antitoxin genes
#18DNABII VACCINES AND ANTIBODIES WITH ENHANCED ACTIVITY
#19METHODS OF PRODUCING GLYCOSYLATED PROTEINS
#20VACCINE TO PROTECT A PIG AGAINST ACTINOBACILLUS PLEUROPNEUMONIAE
#21Compositions and treatments for
#22Vaccines targeting H. influenzae
#23Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens
#24Tetanus toxoid and CCL3 improve DC vaccines
#25Immunogenic compositions comprising polypeptides and fusions thereof
#26Proteins and immunizing compositions containing proteins and methods of use
#27Methods and compositions for assessing antibody specificities
#28SEPTAPEPTIDES ASSOCIATED WITH NEURODEGENERACY
#29Biomarkers for detecting microbial infection
#30Fusion proteins and combination vaccines comprising Protein E and Pilin A
#31Methods and compositions for improved expression of recombinant proteins
#32Proteins and immunizing compositions containing pasteurella proteins and methods of use
#33Conjugated vaccine carrier proteins
#34Methods and compositions for assessing antibody specificities
#35DNABII vaccines and antibodies with enhanced activity
#36ANTIGENS AND ANTIGEN COMBINATIONS
#37Immunogenic Compositions and Vaccines Derived From Bacterial Surface Receptor Proteins
#38ACTINOBACILLUS PLEUROPNEUMONIAE RECOMBINANT TOXIN PROTEIN AND APPLICATION THEREOF
#39ATTENUATED MANNHEIMIA HAEMOLYTICA STRAINS
#40Methods of producing glycosylated proteins
#41Recombinant lactic acid bacteria and the use thereof in oral universal influenza vaccine
#42Compositions and treatments for
#43Methods and compositions for assessing antibody specificities
#44Tetanus toxoid and CCL3 improve DC vaccines
#45Fusion proteins and combination vaccines comprising haemophilus influenzae Protein E and Pilin A
#46Immunogenic compositions comprising polypeptides and fusions thereof
#47NON-TYPEABLE HAEMOPHILUS INFLUENZAE VACCINES AND THEIR USES
#48Use of glycerol with limited feed of carbohydrates for fermentation
#49Multiple variants of meningococcal protein NMB1870
#50Surface exposed protein (protein E; pE)
#51Attenuated strains
#52Attenuated vaccines and methods of making and use
#53type IV pili
#54Capsular polysaccharide solubilisation and combination vaccines
#55Fusion proteins and combination vaccines comprising protein E and pilin A
#56Attenuated Mannheimia haemolytica
#57Immunogenic compositions and vaccines derived from bacterial surface receptor proteins
#58GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HEAMOPHILUS INFLUENZAE
#59Tetanus toxoid and CCL3 improve DC vaccines
#60Fusion proteins and combination vaccines comprising Protein E and Pilin A
#61Attenuated strains
#62Process for stabilizing an adjuvant containing vaccine composition
#63Attenuated mannheimia haemolytica vaccines and methods of making and use
#64COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS
#65type IV pili
#66Cytolethal distending toxin subunit B conjugated or fused to toxin lethal factor
#67GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES
#68Surface exposed protein (protein E; pE)
#69Vaccines against pathogenic and methods of using the same
#70Mutant bacteria for production of generalized modules for membrane antigens
#71Multiple variants of meningococcal protein NMB1870
#72HAEMOPHILUS INFLUENZAE TYPE B
#73EXTRACELLULAR MATRIX PROTEINS FROM HAEMOPHILUS INFLUENZAE BIOFILMS: TARGETS FOR THERAPEUTIC OR DIAGNOSTIC USE
#74CHIMERA COMPRISING BACTERIAL CYTOTOXIN AND METHODS OF USING THE SAME
#75GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HEAMOPHILUS INFLUENZAE
#76Antigens and antigen combinations
#77Attenuated fhaC mutants of bacteria and vaccine compositions thereof
#78Fusion proteins and combination vaccines comprising Protein E and Pilin A
#79Fusion proteins and combination vaccines comprising Protein E and Pilin A
#80type IV pili
#81BINDING MOIETIES FOR BIOFILM REMEDIATION
#82NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE)
#83Treatment and prevention of infections
#84Prion disease-specific epitopes and methods of use thereof
#85Surface exposed protein (protein; pE)
#86Polypeptides from non-typeable
#87PASTEURELLACEAE VACCINES
#88Attenuated mannheimia haemolytica vaccines and methods of making and use
#89Process for stabilizing an adjuvant containing vaccine composition
#90Genes of an otitis media isolate of nontypeable
#91GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HAEMOPHILUS INFLUENZAE
#92Fusion proteins and combination vaccines comprising Protein E and Pilin A
#93ANTIGENIC GLY1 POLYPEPTIDES
#94Outer membrane proteins of and methods thereof
#95Immunogenic compositions comprising polypeptides and fusions thereof
#96polypeptides and methods of use
#97Chimeric vaccine for -induced disease
#98VACCINE COMPRISING INACTIVATED CELLS OF HAEMOPHILUS PARASUIS BACTERIA OF SEROTYPE 5
#99Genes of an otitis media isolate of nontypeable
#100Nucleic acids encoding GAS57 mutant antigens
#101EXTRACELLULAR MATRIX PROTEINS FROM HAEMOPHILUS INFLUENZAE BIOFILMS: TARGETS FOR THERAPEUTIC OR DIAGNOSTIC USE
#102Process for the production of immunogenic compositions
#103Cytolytic RTX-Toxin From Gallibacterium Anatis
#104Modified live (JMSO strain) vaccine
#105Anti-bacterial vaccine compositions with a mutated yleA gene
#106MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NMB1870
#107Multiple variants of meningococcal protein NBM1870
#108POLYPEPTIDES FROM NON-TYPEABLE HAEMOPHILUS INFLUENZAE
#109Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
#110HAEMOPHILUS INFLUENZAE TYPE B
#111Nontypable antigens
#112Chimera comprising bacterial cytotoxin and methods of using the same
#113Compositions for the treatment of cancer, and methods for testing and using the same
#114Attenuated gram negative bacteria
#115Identification of antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
#116Genes of an otitis media isolate of nontypeable
#117FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS
#118Compositions and methods for the removal of biofilms
#119Nontypeable Haemophilus Influenzae Virulence Factors
#120Non-typeable vaccines and their uses
#121type IV pili
#122Selected nucleotide sequences isolated from pathogenic strains of haemophilus influenzae
#123Genes of an otitis media isolate of nontypeable
#124BASB 205 POLYPEPTIDES AND POLYNUCLEOTIDES FROM HAEMOPHILUS INFLUENZAE
#125GAS57 mutant antigens and GAS57 antibodies
#126Heterologous protection against provided by fur cells and the outer-membrane protein extracts thereof
#127Chimeric vaccine for -induced disease
#128Identification of antigens for use in the diagnosis, treatment and monitoring of periodontal diseases
#129Treatment and prevention of infections
#130Modified leukotoxin gene and protein
#131Anti-bacterial Vaccine Compositions
#132Genes of an otitis media isolate of nontypeable
#133Polypeptides from non-typeable
#134METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
#135Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#136Polynucleotides of and its use
#137System and method for identifying complex patterns of amino acids
#138REPLIKINS AND METHODS OF IDENTIFYING REPLIKIN-CONTAINING SEQUENCES
#139REPLIKIN PEPTIDES AND ANTIBODIES THEREFOR
#140PROTEIN D - AN IGD-BINDING PROTEIN OF HAEMOPHILUS INFLUENZAE
#141MAGE3 polypeptides
#142Process for the production of immunogenic compositions
#143Nontypeable virulence factors
#144METHOD AND COMPOSITIONS FOR MODULATING TH17 CELL DEVELOPMENT
#145Genes of an otitis media isolate of nontypeable
#146Immunogenic compositions comprising polypeptides and fusions thereof
#147Haemophilus Influenzae Type B
#148Histophilus Somni Polynucleotides, Polypeptides and Methods of Use
#149REPLIKIN PEPTIDES IN RAPID REPLICATION OF GLIOMA CELLS AND IN INFLUENZA EPIDEMICS
#150Attenuated gram negative bacteria
#151Magnetic resonance contrast medium containing an iron-binding protein
#152Surface exposed protein (protein E; pE)
#153Vaccine for preventing and treating porcine progressive atrophic rhinitis
#154Process for stabilizing an adjuvant containing vaccine composition
#155Composition for treating porcine progressive atrophic rhinitis and making process thereof
#156Attenuated yiaO mutants of bacteria
#157VACCINE
#158Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#159Capsular polysaccharide solubilisation and combination vaccines
#160Capsular polysaccharide solubilisation and combination vaccines
#161Capsular polysaccharide solubilisation and combination vaccines
#162Capsular polysaccharide solubilisation and combination vaccines
#163outer membrane protein and use thereof in vaccination
#164Vaccine Composition
#165Mutants of the P4 protein of nontypable with reduced enzymatic activity
#166Identification of antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
#167REPLIKIN PEPTIDES AND ANTIBODIES THEREFORE
#168SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS
#169Capsular polysaccharide solubilisation and combination vaccines
#170Capsular polysaccharide solubilisation and combination vaccines
#171Capsular polysaccharides solubilisation and combination vaccines
#172Compositions for the treatment of cancer, and methods for testing and using the same
#173Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
#174SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES
#175SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES
#176SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES
#177type IV pili
#178Chimeric vaccine for -induced disease
#179Nontypeable virulence factors
#180Replikins and methods of identifying replikin-containing sequences
#181Polypeptides from non-typeable
#182Polypeptide from haemophilus influenzae
#183Haemophilus influenzae BASB206 gene and protein
#184Modified leukotoxin protein
#185Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
#186Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
#187Immunological combination compositions and methods
#188Virulence-Associated Adhesins
#189Genes of an otitis media isolate of nontypeable
#190Methods for reducing nasopharyngeal colonization of non-typable with synthetic chimeric fimbrin peptides
#191Anti-bacterial vaccine compositions
#192MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE, VACCINE COMPRISING THE SAME AND USE THEREOF
#193Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
#194Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
#195Compositions capable of facilitation penetration across a biological barrier
#196Selected nucleotide sequences isolated from pathogenic strains of
#197Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using the same
#198Probes and primers for detection of bacterial pathogens and antibiotic resistance genes
#199Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
#200Novel polypeptides encoded by essential bacterial genes
#201Methods of producing recombinant protein D
#202Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#203Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
#204Co-expression of recombinant proteins
#205Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
#206Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
#207Vaccine
#208Amino acid sequences capable of facilitating penetration across a biological barrier
#209Haemophilus influenza outer membrane protein and use thereof in vaccination
#210Multiple variants of meningococcal protein nmb1870
#211Vaccine composition
#212Identification of antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
#213Bacterial virulence genes
#214Immunological combination compositions and methods
#215Novel purified polypeptides from haemophilus influenzae
#216outer membrane protein P1pE as a vaccine or vaccine component against shipping fever
#217Live attenuated vaccine against porcine pleuropneumonia
#218Antigens for actinobacillus pleuropneumoniae and methods thereof
#219Vaccine for preventing and treating porcine progressive atrophic rhinitis
#220Identification of antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
#221System and method for identifying complex patterns of amino acids
#222Critical genes and polypeptides of haemophilus influenzae and methods of use
#223Selected nucleotide sequences isolated from pathogenic strains of
#224Mutants of the P4 protein of nontypable with reduced enzymatic activity
#225Polypeptide encoded by a nucleotide sequence of a nontypeable strain of genome
#226Amino acid sequences capable of facilitating penetration across a biological barrier
#227type IV pili
#228Compositions capable of facilitating penetration across a biological barrier
#229Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
#230Novel compounds
#231Vaccines comprising acapsular deletion mutants
#232Capsular polysaccharide solubilisation and combination vaccines
#233Methods of modulating activity of DXR
#234Selected nucleotide sequences isolated from pathogenic strains of Haemophilus influenzae
#235High molecular weight surface proteins of non-typeable Haemophilus
#236Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
#237Phage-display peptides as novel antimicrobial agents against
#238Anti-bacterial vaccine compositions